Halozyme Therapeutics to Hold Pipeline Update Conference Call o... ( SAN DIEGO July 31 /- Halozyme The...)

Halozyme Therapeutics to Hold Pipeline Update Conference Call on August 8

Date:7/31/2008

SAN DIEGO, July 31 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that it will release financial results for the three and six months ended June 30, 2008 before market open on Friday, August 8, 2008.

Jonathan Lim, MD, President and Chief Executive Officer, Gregory Frost, PhD, Vice President and Chief Scientific Officer, Robert Little, Vice President and Chief Commercial Officer, David Ramsay, Vice President and Chief Financial Officer, and Robert Uhl, Senior Director, Investor Relations, will host an investment community conference call beginning at 8:00 a.m. PT (11:00 a.m. ET) on Friday, August 8, 2008, to provide a pipeline update.

Individuals interested in participating in the conference call may do so by dialing 888-256-9044 for domestic callers or 706-643-5585 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of the Company's web site at http://www.halozyme.com. A replay will be available on Halozyme's web site for 30 days. A telephone replay will be available for 48 hours by dialing 800-642-1687 from the U.S., or 706-645-9291 for international callers, and entering reservation code 57745069.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the drug delivery, metabolism, oncology and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the f
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine news :

1. Halozyme Therapeutics Added to Nasdaq Biotech Index
2. Prime Therapeutics Receives TIPPS Certification
3. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
4. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
5. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
6. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
7. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
8. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
9. Prime Therapeutics Announces URAC Accreditation
10. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
11. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting

Post Your Comments:

(Date:12/3/2009)...rn causes demand for affordable drug and alcohol r... sharp increase in demand for its services and att... led to an increase in alcoholic binge drinking, d... (PRWEB) December 3, 2009 -- Mountainside ...spike in demand for its services due to the econom...

(Date:12/3/2009)... of screening test, researcher says, , ...rch points to the possibility of a genetic link be...h high blood pressure who had a gene variant that ...d to be twice as likely as those without the varia...nd. , The finding may lead to a way to identify...

(Date:12/3/2009)...ewswire-USNewswire/ -- The American Association fo...rom one of the largest studies to date on passive ...e Northern California Cancer Center (NCCC) . ,...d cigarettes and who were exposed to secondhand ci...dulthood--had a significantly increased breast can...

(Date:12/3/2009)...PRNewswire-USNewswire/ -- The Board of Trustees of...mously voted to elect three new members during its... is co-founder and Managing Director of De Novo Ve...650 million from three funds in early stage medica...ded Medicus Venture Partners in 1989. He has inves...

(Date:12/3/2009)... For California,s 3.4 million owne...remains one of the most significant threats to not...o their business,s viability. ,, "As the reces...ners of small businesses are recognizing the need ...ed disability coverage," said Michael Hagedorn, ...

Breaking Medicine News(10 mins):Health News:Economic Crisis Causes Acute Demand for Affordable Drug Addiction Treatment 2 Health News:Vitamin D May Be Tied to Heart Disease Via Genes 2 Health News:Northern California Cancer Center's Findings on Breast Cancer and Secondhand Smoke Released Internationally by the American Association for Cancer Research 2 Health News:Salk Institute Board of Trustees Elects Leaders in Venture Capital and Publishing to its Membership 2 Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 2 Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 3 Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 4

[0] Economic Crisis Causes Acute Demand for Affordable Drug Addiction Treatment [0] Vitamin D May Be Tied to Heart Disease Via Genes [2] Northern California Cancer Center's Findings on Breast Cancer and Secondhand Smoke Released Internationally by the American Association for Cancer Research [0] Salk Institute Board of Trustees Elects Leaders in Venture Capital and Publishing to its Membership [1] New Disability Income Insurance Options Provide More Choice for California's Small Business Owners

...ealth Status; Anthem Blue Cross and Blue, Shield p...more than 5,000, Kentuckians located in the easte...LLE, Ky., Nov. 14 Anthem Blue Cross and Blue,Shie...tate. Anthem has assembled a dedicated team to col...

...s first diagnosed in childhood , , WEDNESD...be 87 years old, but he still remembers the day ...1925. , "I went to the hospital at five years of a...aid Cleveland, of Syracuse, N.Y. , He didn,t die....

...f frustration from,those who live with the risk of...tudies suggest that the comprehensive and often co...ming diabetes patients to the point,of inaction. S...ss of incorporating a complete diabetes management...

...uarter Ended September 30, 2007 ...348 Average Patient Charge (APC) ... uncompensated care as a percent of gross revenue .../Metro,Corporation (Nasdaq: RURL ), a leading pro...

...rug development platform, SEATTLE, Nov. 14 Analy... the progress and prospects of three of Cell,Thera...IC) oncology drug,candidates, as well as informati...Strategies, New Opportunities",in New York on Frid...

...tal, the nation,s,largest and most experienced den...Award from Benefits Selling magazine as the dental... design and network availability. The,awards were ...rences in eight categories that are determined to,...

Anthem Blue Cross and Blue Shield in Kentucky Announces Release of State Health Index A Full and Long Life, Despite Diabetes Natural Antioxidants Help Reduce Oxidative Stress in Diabetes Treatment Rural/Metro Announces Results for Fiscal 2008 First Quarter; Fiscal 2007 Fourth Quarter and Full Year Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.'s Drug Pipeline Brokers Name Delta Dental the Best in Coverage, Plan Design and Networks

(Date:12/3/2009)..., ALISO VIEJO, Calif. and STATE COLLEGE, Pa., Dec...s today announced the signing of an agreement to p...sing SoftGenetics, NextGENe software for next-gene..., (Logo: http://www.newscom.com/cgi-bin/prnh/... Ambry,s CSO said, "Our team at Ambry has been pro...

(Date:12/3/2009)... , DOYLESTOWN, Pa., Dec. 3 /PRNewswire-FirstCa... Corporation, (Nasdaq: QGLY ) www.quigleyco.com ...s evaluation of its opportunities to develop presc...ncluded that it is in its best interests to focus ...ich may include but are not limited to its Cold-EE...

(Date:12/3/2009)..., WILMINGTON, Del., Dec. 3 Parag...rmaceutical risk management and optimal medication...9, on the FDA,s draft guidance on REMS - Risk Eval...ications for REMS lifecycle management. Dr. Gary ...expert on REMS and risk management programs, will ...

Breaking Medicine Technology:Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2 Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3 Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 2 Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 3 Photo 3A Stopain and the Arthritis Foundation Join Forces to Promote the Benefits of Staying Active 54192 1 Photo 3A Stopain and the Arthritis Foundation Join Forces to Promote the Benefits of Staying Active 54192 2 Prime Therapeutics 2009 Drug Trend Insights Shows Drug Spending Slows to Lowest Rate on Record 54189 1 Prime Therapeutics 2009 Drug Trend Insights Shows Drug Spending Slows to Lowest Rate on Record 54189 2 Prime Therapeutics 2009 Drug Trend Insights Shows Drug Spending Slows to Lowest Rate on Record 54189 3 Ranbaxy Receives Final Approval To Market Sumatriptan Succinate Tablets 54186 1 Ranbaxy Receives Final Approval To Market Sumatriptan Succinate Tablets 54186 2

[0] Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects [0] Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution [0] Webinar to Explore FDA Draft REMS Guidance and Its Implications for Lifecycle Management

...te phase III trial - , , SOUTH SAN FRANCISCO, Cal...nnounced top-line results from their phase II stud...ders. The data was presented on March 27th at the...ican College of Medical Genetics by Brendan Lee, M...igator and Professor Department of Molecular and H...

... in combination with the most commonly used doses ...tients with mixed dyslipidemia , , ORLANDO, Fla.,...tt ,s TRILIPIX(R) (fenofibric acid) delayed-releas...m met all of the study,s primary endpoints. TRILI...m 5 mg significantly improved HDL cholesterol and ...

Other Medicine Technology:Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders 2 Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders 3 Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders 4 New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 2 New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 3 New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 4 New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 5

Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management

...eye protection Properly manufactured radiation pr...f scatter radiation. Our high quality frames and m...h minimized weight. Our lenses are made of Schott ... standards. Most Pulse Glasses are offered with le...

...re designed with the safety and comfort of the pra...lso called SF-6) leaded glass, the industry standa...t standards, as set for optical clarity, visible l...While our eyewear is protecting your eyes, it also...

Glasses,metal,trifocal

Medicine Products:

Wrap Metal Standard Wrap Around Frame Glasses,metal,trifocal

Halozyme Therapeutics to Hold Pipeline Update Conference Call o...( SAN DIEGO July 31 /- Halozyme The...),Health